Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YOSEMITE phase 3 study of zodasiran in homozygous familial hypercholesterolemia
NL-OMON59699Phase 3Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Feb 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of zodasiran in homozygous familial hypercholesterolemia (HoFH), sponsored by Arrowhead Pharmaceuticals. Started Feb 2026; status: completed.
02
Drugs
zodasiran
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NL-OMON59699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59699.